Figure 9. Activity of ML223 in a CBFB-MYH11 knock-in mouse model of leukemia.

Figure 9Activity of ML223 in a CBFB-MYH11 knock-in mouse model of leukemia

(left) Reduced leukemia cell burden in mice treated with probe compound ML223. Cyt: cytarabine. Dox: doxorubicin. The data were collected 10 days after treatments started. N = 6 for each group except for saline, which had 5 mice. Leukemia cell percentages were represented by c-kit positive cells. (right) Survival of leukemic mice treated with probe compound ML223 and standard of care compound cytarabine (Cyt). Control mice were given saline and Cyt mice were given cytarabine on days 10–15 after injecting CBF leukemia cells. ML223 was given on days 10–40 at 300 mg/kg/p.o. The data showed potential synergy between cytarabine and ML223.

From: ML223: A Small Molecule Probe With In Vivo Activity Against Acute Myeloid Leukemia Subtype M4Eo

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.